Data collected on patients seen from September 1, 1996, to December 31 ... [9] Consequently, a group of pulmonary hypertension specialists initiated a voluntary collaborative survey entitled ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

Weiss and Robb 1 have described the mechanism ... all of whom had moderate to marked pulmonary hypertension. The average pulmonary-artery pressure for this group was 61 systolic, 33 diastolic.

and reduced risk of clinical worsening events for people with WHO group 1 pulmonary hypertension. These "dramatic" benefits in ZENITH provide a mandate for use, noted study discussant Anjali ...

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR ™ (sotatercept-csrk) compared to ...

A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial ...

Pulmonary arterial hypertension (PAH ... compared with 54.7% in the placebo group (p<0.0001). The trial has shown that adding sotatercept to the maximum-tolerated standard treatment for PAH ...

Pulmonary arterial hypertension (PAH ... The result: In the sotatercept group, the risk of deterioration resulting in a longer hospital stay, a lung transplant or even death was reduced by ...

Figure 1: Serine elastase inhibition induces survival by reversal of pulmonary hypertension ... were alive at 28 days (only one died in each group). When treated with the elastase inhibitor ...

in the placebo group; lung transplantation in 1 patient (1.2%) and 6 patients (7.0%), respectively; and hospitalization for worsening pulmonary arterial hypertension in 8 patients (9.3% ...